vigamox
novartis slovakia s.r.o., slovensko - moxifloxacín - 64 - ophthalmologica
sandostatin lar 10 mg
novartis slovakia s.r.o. - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
súprava aplikačná visisure na podanie lieku
novartis pharma ag lichtstrasse 35 4056 basel Švajčiarsko -
kesimpta
novartis ireland ltd - ofatumumab - roztrúsená skleróza, recidivujúce-odosielajúcej - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
premier klercide-cr sterile biocide b spray novartis
ecolab deutschland gmbh -
aclasta
sandoz pharmaceuticals d.d. - kyselina zoledrónová - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lieky na liečbu chorôb kostí - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. liečba osteoporózy priradené dlhodobé systémové glukokortikoidy terapia v post-menopauzálnych žien a u mužov zvýšené riziko zlomeniny. liečba paget je ochorenie kostí.
atriance
sandoz pharmaceuticals d.d. - nelarabín - prekurzor t-bunkovej lymfoblastickej leukémie-lymfómu - antineoplastické činidlá - nelarabine je indikovaný na liečbu pacientov s t-buniek acute lymphoblastic leukémia (t-all) a t-buniek lymphoblastic lymfóm (t-lbl), ktorých ochorenie má neodpovedali, alebo má relapsed po liečbe aspoň dve chemoterapie režimy. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
azarga
novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmologiká - zníženie vnútroočného tlaku (iop) u dospelých pacientov s otvoreným uhlom alebo očných hypertenzia, pre ktorých monotherapy poskytuje dostatočné zníženie iop.
copalia
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - vysoký tlak - Činidlá pôsobiace na systém renín-angiotenzín - liečba esenciálnej hypertenzie. copalia je indikovaný u pacientov, ktorých krvný tlak nie je primerane kontrolované na amlodipine alebo valsartan monotherapy.
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresíva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatická arthritiscosentyx, samostatne alebo v kombinácii s metotrexátom (mtx), je indikovaná na liečbu aktívnej psoriatická artritída u dospelých pacientov, keď reakcia na predchádzajúce ochorenia úprava anti reumatických drog (dmard) terapia bola neprimeraná. axiálne spondyloarthritis (axspa)ankylozujúca spondylitída (as, radiographic axiálne spondyloarthritis)cosentyx je indikovaná na liečbu aktívnej ankylozujúcej spondylitíde u dospelých, ktorí reagovali neadekvátne konvenčná terapia. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.